limit
evid
report
host
cell
respons
pandem
swineorigin
influenza
viru
soiv
infect
human
therefor
investig
proport
peripher
cell
subset
analyz
relationship
helper
subset
chang
cell
activ
infect
found
soivinfect
patient
exhibit
rapid
lymphopenia
cell
activ
preferenti
loss
subset
earli
stage
acut
infect
statist
analysi
indic
deplet
loss
cell
rather
treg
cell
correl
cell
activ
importantli
upregul
like
contribut
function
loss
cell
thu
rapidli
gener
lymphopenia
preferenti
loss
popul
cell
activ
present
characterist
earli
immun
respons
soivinfect
patient
find
therefor
may
help
earlier
diagnosi
studi
immun
pathogenesi
soiv
infect
pandem
swineorigin
influenza
viru
soiv
pandem
acut
respiratori
ill
caus
novel
influenza
strain
first
emerg
human
mexico
march
sinc
soiv
spread
rapidli
across
globe
result
sustain
commun
transmiss
countri
five
contin
cumul
case
least
death
novemb
incub
period
soiv
infect
usual
day
clinic
manifest
often
includ
fever
cough
stethocatharsi
pharyngodynia
headach
myalgia
diarrhea
vomit
sever
case
rapidli
progress
respiratori
failur
multipl
organ
failur
therefor
identif
earli
immunolog
paramet
critic
studi
pathogenesi
diseas
increas
evid
suggest
host
immun
respons
play
critic
role
determin
variou
outcom
influenza
viru
infect
moder
increas
proinflammatori
activ
virusinfect
patient
may
favor
viru
clearanc
howev
hyperactiv
inflammatori
respons
may
lead
detriment
effect
host
exampl
known
high
mortal
rate
pathogen
avian
influenza
viru
infect
consequ
overact
inflammatori
respons
sever
diseas
close
relat
virusinduc
cytokin
storm
sever
acut
respiratori
syndrom
reinforc
concept
overact
inflammatori
respons
associ
progress
pulmonari
infiltr
necrosi
tissu
destruct
abund
virusinduc
inflammatori
cytokin
innat
immun
activ
lead
subsequ
antigennonspecif
cell
activ
mice
human
viral
infect
furthermor
pathogenesi
induc
activ
nonspecif
cell
liver
rel
tissu
demonstr
human
chronic
hiv
hbv
hcv
infect
type
ifn
play
crucial
role
induc
system
inflamm
loss
lymphocyt
number
earli
stage
viral
infect
studi
provid
evid
link
system
inflammatori
activ
activ
nonspecif
cell
induc
tissu
damag
helper
cell
gener
orchestr
host
immun
respons
releas
distinct
cytokin
profil
subset
secret
endogen
convent
thought
exacerb
tissu
damag
control
viral
infect
regulatori
cell
treg
immunosuppress
play
import
role
regul
immun
respons
cell
produc
proinflammatori
cytokin
causal
relat
chronic
inflamm
host
defens
pulmonari
microbi
agent
recent
report
demonstr
cell
play
import
role
protect
mice
lethal
dose
influenza
challeng
furthermor
hypercytokinemia
earli
host
respons
signatur
observ
sever
pandem
influenza
howev
whether
chang
helper
subset
could
bridg
inflammatori
activ
cell
activ
hostpathogen
interact
earli
stage
infect
welldefin
address
issu
mention
comprehens
analyz
peripher
cell
subset
acut
soivinfect
patient
found
rapidli
gener
lymphopenia
preferenti
loss
popul
patient
earli
stage
acut
soiv
infect
subsequ
associ
cell
activ
find
may
help
studi
pathogenesi
diseas
blood
sampl
collect
confirm
soivinfect
patient
healthi
control
diagnos
compli
diagnos
criteria
global
influenza
program
briefli
laboratori
diagnosi
soiv
made
rtpcr
combin
nasal
throat
swab
primer
design
chines
nation
influenza
center
individu
concurr
hepat
c
viru
hepat
b
viru
infect
autoimmun
diseas
met
clinic
biolog
criteria
bacteri
fungal
infect
exclud
patient
assign
three
group
accord
day
first
clinic
manifest
earli
stage
group
n
defin
patient
enrol
within
day
onset
clinic
symptom
soiv
intermedi
stage
group
n
defin
patient
enrol
day
onset
clinic
symptom
soiv
late
stage
group
n
defin
patient
enrol
suffer
soiv
infect
day
patient
hospit
followedup
unit
beij
hospit
treat
oseltamivir
immedi
accord
treatment
recommend
none
patient
develop
sever
statu
throughout
treatment
period
accord
guidelin
pharmacolog
manag
pandem
influenza
influenza
virus
group
convalesc
stage
defin
period
begin
day
therapi
twentyon
ageand
sexmatch
healthi
individu
enrol
control
studi
protocol
approv
ethic
committe
unit
written
inform
consent
obtain
subject
basic
characterist
subject
list
tabl
plasma
store
prior
analysi
antibodi
purchas
bd
bioscienc
san
jose
ca
usa
except
phycoerythrin
pe
conjug
mab
fluorescein
isothiocyan
fitc
conjug
ebiosci
san
diego
ca
cell
count
cocktail
mab
beckmancoult
specif
cell
use
directli
measur
peripher
blood
cell
count
determin
cell
surfac
activ
marker
cocktail
mab
includ
pe
conjug
allophycocyanin
apc
conjug
peridin
chlorophyl
protein
conjuct
antihladr
fitcconjug
antibodi
use
determin
frequenc
treg
peripher
blood
percp
conjug
apc
conjug
pe
conjug
fitcconjug
use
isotyp
control
antibodi
use
separ
posit
neg
cell
percp
fitc
pe
apc
fluoresc
channel
cell
incub
stain
dark
min
blood
lyse
lyse
solut
bd
pharmingen
san
jose
ca
intracellular
stain
cell
permeabil
stain
fitcconjug
fix
use
ebiosci
fixperm
accord
manufactur
instruct
intracellular
stain
fresh
heparin
peripher
blood
incub
pma
ngml
ionomycin
rpmi
medium
supplement
fetal
calf
serum
fc
h
monensin
ad
hour
incub
blood
lyse
lyse
solut
permeabil
stain
correspond
intracellular
antibodi
fix
analyz
use
facscalibur
flowjo
softwar
treestar
ashland
usa
previous
describ
investig
whether
inhibit
cell
function
vitro
isol
peripher
blood
mononuclear
cell
pbmc
cellswel
incub
ubottom
plate
differ
concentr
iu
ml
iuml
iuml
cell
stimul
pma
ngml
ionomycin
h
perform
intracellular
stain
accord
aforement
protocol
plasma
level
measur
quantit
sandwich
elisa
follow
manufactur
instruct
r
system
minneapoli
mn
usa
minim
detect
concentr
pgml
pgml
intraassay
interassay
coeffici
variat
elisa
b
respect
sampl
measur
duplic
data
analyz
use
spss
softwar
spss
inc
chicago
illinoi
summar
mean
standard
deviat
comparison
variou
individu
perform
use
mannwhitney
utest
comparison
individu
perform
use
wilcoxon
match
pair
test
correl
analysi
evalu
spearman
rank
correl
test
test
p
b
consid
statist
signific
use
flow
cytometr
analysi
first
compar
absolut
number
circul
cell
patient
acut
convalesc
stage
soiv
infect
healthi
control
individu
shown
fig
patient
infect
soiv
clearli
experienc
cell
loss
peripher
blood
acut
stage
infect
mean
absolut
cell
count
healthi
individu
respect
wherea
patient
soiv
infect
markedli
lower
respect
among
patient
patient
earli
clinic
onset
show
lower
cell
count
cell
cell
cell
count
progress
increas
patient
intermedi
cell
late
stage
cell
data
show
soiv
infect
lead
rapid
deplet
cell
earli
stage
day
follow
rapid
signific
restor
cell
day
onset
ill
howev
dispar
pattern
cell
restor
observ
patient
earli
intermedi
stage
oseltamivir
therapi
shown
fig
absolut
cell
count
almost
doubl
cell
subset
compar
within
patient
earli
convalesc
stage
cell
howev
absolut
cell
count
cell
subset
show
decreas
trend
compar
within
patient
intermedi
convalesc
stage
cell
observ
signific
differ
absolut
cell
count
cell
subset
within
patient
late
convalesc
stage
analyz
hladr
antigen
express
patient
shown
fig
found
acut
soivinfect
patient
earli
stage
higher
percentag
hladr
cell
hladr
healthi
control
hladr
contrast
observ
upregul
express
signific
differ
hladr
express
cell
acut
soivinfect
compar
frequenc
cell
treg
peripher
blood
healthi
control
acut
soivinfect
patient
shown
fig
b
distribut
subset
soivinfect
subject
differ
hc
subject
found
absolut
cell
count
treg
cell
significantli
decreas
soivinfect
patient
versu
hc
individu
particular
patient
convalesc
stage
fullscal
restor
cell
understand
whether
loss
cell
subset
patient
soiv
infect
select
simpli
due
gener
cell
deplet
investig
specif
rel
frequenc
subset
popul
found
percentag
cell
significantli
increas
soivinfect
patient
compar
hc
individu
p
fig
furthermor
averag
frequenc
patient
convalesc
stage
even
increas
patient
earli
stage
p
b
data
agre
previou
report
cell
play
import
role
viral
clearanc
contrast
averag
frequenc
earli
clinic
onset
significantli
decreas
soivinfect
patient
compar
hc
subject
show
gradual
increas
earli
late
phase
fig
c
howev
differ
treg
frequenc
soivinfect
patient
hc
data
suggest
cell
prone
deplet
earli
stage
soiv
infect
investig
impact
cell
deplet
cell
activ
found
signific
neg
correl
cell
count
frequenc
hladr
cell
soivinfect
subject
earli
clinic
onset
fig
b
analysi
indic
neg
associ
occur
frequenc
treg
subset
togeth
result
demonstr
deplet
select
loss
cell
treg
cell
strongli
associ
increas
immun
activ
earli
phase
soiv
infect
earli
virusinduc
peak
cell
attrit
shown
correl
peak
virusinduc
mice
examin
serum
concentr
address
whether
associ
decreas
cell
soivinfect
patient
expect
serum
highli
upregul
soivinfect
patient
compar
healthi
control
fig
analysi
indic
patient
earli
stage
lowest
serum
concentr
fig
determin
whether
influenc
cell
vitro
shown
fig
observ
cell
presenc
significantli
reduc
surprisingli
found
secret
cell
slightli
increas
presenc
pool
data
confirm
result
consist
five
healthi
control
three
independ
detect
fig
taken
togeth
data
suggest
soiv
infectioninduc
may
partli
constrict
function
cell
soiv
caus
outbreak
febril
respiratori
infect
rang
selflimit
sever
ill
howev
littl
known
immun
respons
develop
soiv
previou
studi
hypothes
virusinduc
lymphopenia
earli
infect
benefici
pathogen
control
perform
comprehens
investig
peripher
lymphocyt
subset
differ
stage
infect
compar
within
soivinfect
patient
convalesc
stage
result
demonstr
rapid
gener
lymphopenia
patient
soiv
earli
stage
infect
patient
recov
initi
ill
equal
rapid
dramat
restor
cell
count
seen
peripher
blood
data
support
notion
earli
loss
cell
may
allow
antigenspecif
expans
cell
also
found
number
subset
rel
preferenti
decreas
soivinfect
patient
compar
cell
subset
includ
cell
treg
cell
cell
play
import
role
host
defens
pulmonari
microbi
agent
recent
studi
indic
protect
mice
lethal
dose
influenza
challeng
data
suggest
cell
might
activ
particip
immun
regul
soivinfect
patient
although
precis
mechan
cell
induc
cell
activ
soivinfect
patient
remain
unknown
present
studi
indic
loss
subset
may
link
inflammatori
respons
cell
activ
earli
hostpathogen
interact
three
piec
evid
support
notion
first
similar
recent
report
macaqu
infect
siv
anim
model
immunodefici
viru
infect
similar
acut
human
infect
found
significantli
decreas
frequenc
cell
increas
level
soivinfect
patient
addit
present
studi
also
found
frequenc
cell
treg
cell
neg
correl
cell
activ
third
highli
induc
acut
infect
direct
respons
viral
replic
exhibit
consider
inhibitori
effect
cell
reminisc
found
soivinfect
patient
earli
phase
result
suggest
cell
close
associ
inflammatori
activ
cell
activ
acut
soiv
infect
howev
observ
associ
loss
sever
soiv
infect
cell
produc
cocktail
cytokin
futur
studi
investig
whether
cell
soivinfect
patient
function
skew
enhanc
inflammatori
cytokin
decreas
antiinflammatori
cytokin
notabl
differ
time
respons
observ
soivinfect
patient
studi
recent
report
regard
sever
soiv
infect
studi
perform
mice
model
ifninduc
cell
lose
observ
mice
model
immedi
infect
contrast
soivinfect
patient
usual
identifi
day
soiv
infect
becom
clinic
symptomat
thu
although
found
serum
level
significantli
higher
clinic
onset
infect
healthi
subject
even
loss
cell
respons
presenc
healthi
subject
reminisc
found
soivinfect
patient
earli
phase
time
differ
suggest
preferenti
decreas
popul
earli
soivinfect
patient
may
simpli
direct
result
ifninduc
attrit
altern
explan
data
commit
cell
still
peripher
blood
downregul
synthesi
presenc
cell
migrat
lung
tissu
lymph
node
contrast
recent
data
publish
bermejomartin
jf
observ
similar
level
plasma
soivinfect
patient
howev
observ
associ
level
sever
soiv
infect
summari
studi
provid
first
indic
soiv
infect
lead
rapid
gener
lymphopenia
preferenti
loss
popul
patient
earli
stage
infect
subsequ
associ
cell
activ
clinic
characterist
may
facilit
earlier
diagnosi
studi
pathogenesi
soiv
infect
